Confounding adjustment with propensity scores for overlap weighting in observational studies: a concise primer.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
John G Rizk
{"title":"Confounding adjustment with propensity scores for overlap weighting in observational studies: a concise primer.","authors":"John G Rizk","doi":"10.1080/17512433.2025.2546151","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Overlap weighting has emerged as a valuable method for addressing confounding in observational studies, particularly in real-world data settings characterized by imbalanced covariates and limited overlap between treatment groups. Its ability to produce stable, interpretable estimates makes it an attractive alternative to inverse probability of treatment weighting (IPTW), which can suffer from extreme weights and instability.</p><p><strong>Areas covered: </strong>This report outlines the methodological basis of overlap weighting and contrasts it with IPTW. The limitations of IPTW are illustrated through a clinical example comparing clopidogrel and prasugrel, where substantial baseline differences lead to poor propensity score (PS) overlap. Overlap weighting is discussed as a solution that emphasizes individuals in clinical equipoise (i.e. PS near 0.5), minimizes the influence of outliers, and achieves exact covariate balance.</p><p><strong>Expert opinion: </strong>Overlap weighting is well-suited for observational studies with moderate to poor overlap and can be considered a preferred approach in many real-world contexts. Presenting results from multiple PS methods, including standardized mortality ratio (SMR) weighting, IPTW, PS adjustment, and overlap weighting, can help assess robustness and enhance the credibility of causal inferences.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"535-541"},"PeriodicalIF":3.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2025.2546151","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Overlap weighting has emerged as a valuable method for addressing confounding in observational studies, particularly in real-world data settings characterized by imbalanced covariates and limited overlap between treatment groups. Its ability to produce stable, interpretable estimates makes it an attractive alternative to inverse probability of treatment weighting (IPTW), which can suffer from extreme weights and instability.

Areas covered: This report outlines the methodological basis of overlap weighting and contrasts it with IPTW. The limitations of IPTW are illustrated through a clinical example comparing clopidogrel and prasugrel, where substantial baseline differences lead to poor propensity score (PS) overlap. Overlap weighting is discussed as a solution that emphasizes individuals in clinical equipoise (i.e. PS near 0.5), minimizes the influence of outliers, and achieves exact covariate balance.

Expert opinion: Overlap weighting is well-suited for observational studies with moderate to poor overlap and can be considered a preferred approach in many real-world contexts. Presenting results from multiple PS methods, including standardized mortality ratio (SMR) weighting, IPTW, PS adjustment, and overlap weighting, can help assess robustness and enhance the credibility of causal inferences.

观察性研究中重叠加权倾向得分的混杂校正:简明入门。
在观察性研究中,重叠加权已成为解决混淆的一种有价值的方法,特别是在以协变量不平衡和治疗组之间重叠有限为特征的现实世界数据设置中。它能够产生稳定的、可解释的估计,这使得它成为处理加权逆概率(IPTW)的一个有吸引力的替代方案,后者可能受到极端权重和不稳定性的影响。涉及领域:本报告概述了重叠加权的方法基础,并将其与IPTW进行了对比。IPTW的局限性通过一个比较氯吡格雷和普拉格雷的临床例子来说明,其中大量的基线差异导致倾向评分(PS)重叠。讨论了重叠加权作为一种解决方案,强调个体在临床平衡(即PS接近0.5),最小化异常值的影响,并实现精确的协变量平衡。其他部分讨论了稳定的权重、最近的文献应用以及对目标估计的考虑。专家意见:重叠加权法非常适合于中度到轻度重叠的观察性研究,在许多现实环境中应被视为首选方法。提出多种PS方法的结果,包括标准化死亡率(SMR)加权、IPTW、PS调整和重叠加权,可以帮助评估稳健性并提高因果推断的可信度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Clinical Pharmacology
Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.30
自引率
2.30%
发文量
127
期刊介绍: Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信